Physiological aspects of the combination of insulin and GLP-1 in the regulation of blood glucose control

Diabetes & Metabolism
Bo Ahrén

Abstract

Combining insulin with glucagon-like peptide-1 (GLP-1) receptor agonists or dipeptidyl peptidase-4 (DPP-4) inhibitors as glucose-lowering therapy for type 2 diabetes is a promising strategy that has gained considerable interest over the past few years. One advantage of this combination is the complementary mechanistic actions of insulin and GLP-1. Insulin increases glucose utilization and retards hepatic glucose production through direct actions in muscle, adipose tissue and the liver. On the other hand, GLP-1 stimulates insulin secretion, inhibits glucagon secretion and retards gastric emptying. Combining these effects results in powerful reductions in both fasting and postprandial glucose through diminished glucose entry into the bloodstream after food consumption, reduced hepatic production of glucose and increased glucose utilization. In addition, GLP-1 receptor agonists induce satiety, leading to decreases in food intakes and body weight, thereby preventing the weight gain often seen with insulin therapy. Clinical trials have verified that these physiological effects as a result of combining insulin with GLP-1 receptor agonists or DPP-4 inhibitors can indeed result in improved glycaemia, with limited risks of hypoglycaemia...Continue Reading

References

Dec 1, 1984·The Journal of Clinical Investigation·H MaruyamaR H Unger
Jul 6, 2001·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·A FlintA Astrup
Jan 19, 2005·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·D D'AlessioR Prigeon
Jul 30, 2005·American Journal of Physiology. Gastrointestinal and Liver Physiology·Dominique DardevetAlan D Cherrington
Dec 15, 2007·Drug News & Perspectives·José Luis González-Sánchez, Manuel Serrano-Ríos
Mar 11, 2009·Frontiers in Bioscience (Landmark Edition)·Dale S EdgertonAlan D Cherrington
Jan 18, 2011·Experimental Cell Research·Bo Ahrén
Jan 5, 2012·The Journal of Clinical Investigation·Roger H Unger, Alan D Cherrington
Jun 8, 2012·Experimental Diabetes Research·Matteo MonamiEdoardo Mannucci
Jul 25, 2012·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Helen BerlieNicole R Pinelli
Oct 16, 2012·Diabetologia·M SeghieriE Ferrannini
Feb 26, 2014·World Journal of Diabetes·Bo Ahrén
Jul 22, 2014·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Adil E BharuchaAlan R Zinsmeister

❮ Previous
Next ❯

Citations

Feb 27, 2016·Journal of Molecular and Cellular Cardiology·Gabriel A GriloLisandra E de Castro Brás
Nov 8, 2018·Journal of Diabetes Research·Bogdan Mircea MihaiCristina Mihaela Lăcătușu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Asprosin

Asprosin is a fasting-induced hormone produced in the white adipose tissue to stimulate the hepatic release of glucose into the bloodstream. Discover the latest research on this protein hormone here.